Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations

Table 1 Characteristics of patients with EGFR/ALK co-alterations

Patients	Age range at diagnosis	TNM stage at diagnosis	Pathological	Metastasis	EGFR type	ALK type
1	50–70	IV	Adenocarcinoma	Node, bone	19del	STRN-ALK
2	50–70	IV	Adenocarcinoma	Multiple metastases	19del	STRN-ALK
3	50–70	IV	Adenocarcinoma	bone	L858R	L1152R
4	50–70	IV	Adenocarcinoma	Unknown	L858R	L1152R
5	50–70	IV	Adenocarcinoma	Brain, bone, liver, node	L858R	EML4-ALK
6	50–70	IV	Adenocarcinoma	Pleura, peritoneum, mesentery	19del	EML4-ALK
7	50–70	IV	Adenocarcinoma	Liver, lung, bone, node	19del	EML4-ALK
8	50–70	IV	Adenocarcinoma	Brain, mediastinum, hilum	G719C + S768I	STRN-ALK
9	50–70	IV	Adenocarcinoma	Multiple metastases	19del	EML4-ALK

ISSN: 1471-2407